Press release
Natural Killer Cell Therapies Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH,
Natural Killer Cell Therapies Pipeline Analysis 2025 by DelveInsight
Natural Killer Cell Therapies Overview:
Natural killer (NK) cells are a type of lymphocyte that serve as essential components of the innate immune system. They are highly specialized immune cells that play a crucial role in the body's defense against tumors and virus-infected cells. In various cancer patients, abnormalities in NK cells have been identified, such as reduced cytotoxic activity, impaired expression of activating receptors or signaling proteins, heightened levels of inhibitory receptors, limited proliferation, lower numbers in the bloodstream and tumor tissue, and disrupted cytokine secretion.
NK cell-based therapies have shown the most promise in treating blood cancers, such as leukemia. NK immunotherapy can be approached in two primary ways: stimulating the body's own NK cells using specific activators or administering externally sourced NK cells through methods like hematopoietic stem cell transplantation (HSCT) or adoptive cell transfer. To date, multiple strategies have been developed to harness NK cells for cancer treatment.
Download our report @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Natural Killer Cell Therapies Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Natural Killer Cell Therapies Therapeutics Market.
Key Takeaways from the Natural Killer Cell Therapies Pipeline Report
DelveInsight's Natural Killer Cell Therapies pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer Cell Therapies treatment.
In June 2024, GT Biopharma announced FDA clearance of its IND application for GTB-3650, an NK cell engager targeting CD33+ leukemia, with Phase 1 trials expected to commence in the second half of 2024.
In April 2024, the FDA approved ANKTIVA (an IL-15 receptor agonist) for BCG-unresponsive non-muscle invasive bladder cancer. This therapy activates the body's NK and T cells to attack tumor cells.
In April 2024, NKGen Biotech received FDA clearance for an Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of SNK01, an autologous NK cell therapy for Parkinson's disease.
Key Natural Killer Cell Therapies companies such as ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others are evaluating new drugs for Natural Killer Cell Therapies to improve the treatment landscape.
Promising Natural Killer Cell Therapies pipeline therapies in various stages of development include Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others.
Natural Killer Cell Therapies Pipeline Analysis
The Natural Killer Cell Therapies pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Natural Killer Cell Therapies Market.
Categorizes Natural Killer Cell Therapies therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Natural Killer Cell Therapies drugs under development based on:
Stage of development
Natural Killer Cell Therapies Route of administration
Target receptor
Monotherapy vs. combination therapy
Natural Killer Cell Therapies Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Natural Killer Cell Therapies Licensing agreements
Funding and investment activities supporting future Natural Killer Cell Therapies market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Natural Killer Cell Therapies Emerging Drugs
Monalizumab: Innate Pharma
NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
ALT 803: ImmunityBio
ALECSAT: CytoVac
PNK-007: Celularity
Natural Killer Cell Therapies Companies
There are over 100 prominent companies actively involved in the development of Natural Killer (NK) Cell Therapies. Among them, Innate Pharma has a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.
DelveInsight's report covers around 140+ products under different phases of Natural Killer Cell Therapies clinical trials like
Natural Killer Cell Therapies Late stage Therapies (Phase III)
Natural Killer Cell Therapies Mid-stage Therapies (Phase II)
Natural Killer Cell Therapies Early-stage Therapies (Phase I)
Natural Killer Cell Therapies Pre-clinical and Natural Killer Cell Therapies Discovery stage Therapies
Natural Killer Cell Therapies Discontinued & Inactive Therapies
Natural Killer Cell Therapies pipeline report provides the Natural Killer Cell Therapies therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Natural Killer Cell Therapies Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Natural Killer Cell Therapies Therapies and Key Natural Killer Cell Therapies Companies: Natural Killer Cell Therapies Clinical Trials and recent advancements https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Natural Killer Cell Therapies Pipeline Therapeutic Assessment
• Natural Killer Cell Therapies Assessment by Product Type
• Natural Killer Cell Therapies By Stage
• Natural Killer Cell Therapies Assessment by Route of Administration
• Natural Killer Cell Therapies Assessment by Molecule Type
Download Natural Killer Cell Therapies Sample report to know in detail about the Natural Killer Cell Therapies treatment market @ Natural Killer Cell Therapies Therapeutic Assessment https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Natural Killer Cell Therapies Current Treatment Patterns
4. Natural Killer Cell Therapies - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Natural Killer Cell Therapies Late-Stage Products (Phase-III)
7. Natural Killer Cell Therapies Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Natural Killer Cell Therapies Discontinued Products
13. Natural Killer Cell Therapies Product Profiles
14. Natural Killer Cell Therapies Key Companies
15. Natural Killer Cell Therapies Key Products
16. Dormant and Discontinued Products
17. Natural Killer Cell Therapies Unmet Needs
18. Natural Killer Cell Therapies Future Perspectives
19. Natural Killer Cell Therapies Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Natural Killer Cell Therapies Pipeline Reports Offerings: https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Natural Killer Cell Therapies Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, here
News-ID: 3961269 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Therapies
GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies, DelveInsight | Pa …
GM1 Gangliosidosis therapies, such as PBGM01, and others, are expected to boost the GM1 Gangliosidosis Market in the upcoming years.
DelveInsight has launched a new report on "GM1 Gangliosidosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the GM1 Gangliosidosis, historical and forecasted epidemiology as well as the GM1 Gangliosidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover…
Facioscapulohumeral Muscular Dystrophy Pipeline Assessment 2024: Therapies, Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Facioscapulohumeral Muscular Dystrophy pipeline constitutes 10+ key companies continuously working towards developing 10+ Facioscapulohumeral Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Facioscapulohumeral Muscular Dystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Facioscapulohumeral Muscular…
Intratumoral Cancer Therapies Market Report 2024 - Intratumoral Cancer Therapies …
"The Business Research Company recently released a comprehensive report on the Global Intratumoral Cancer Therapies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The intratumoral cancer therapies…
Innovative Therapies in Alcohol Rehabilitation
Alcohol rehabilitation has evolved significantly over the years, with innovative therapies emerging as crucial elements in the journey to recovery. These groundbreaking approaches go beyond traditional methods, providing individuals struggling with alcohol addiction with a diverse set of tools to achieve and maintain sobriety. In this article, we delve into innovative therapies, exploring their effectiveness and impact on alcohol rehabilitation if you'd like to know more about alcohol rehab in…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market New Development of No …
A global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies,…
Viral Vector Contract Manufacturing Market Outlook 2021- Gene Therapies, Cell Th …
The latest report released on Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines Market analyses areas where there is still room for improvement. Irrespective of industry, organization size or geographic location, the Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines Market study suggests that advanced technologies are playing a bigger role than ever before. The assessment provides trend,…
